• NEWS & PUBLICATIONS
  • News and Media
  • Newsletters
  • Journals
  • Books
• MEMBERSHIP
  • Join/Renew
  • Benefits
  • Categories
  • Download a Member Application
  • Grants, Awards, and Scholarships
  • Access the Phantom Analysis Toolkit
  • Membership Directory
  • Chapters
  • Centers of Excellence
  • Councils
  • Member Spotlight
  • Women in Nuclear Medicine
  • SNMMI Fellow
  • Council and Center Internships
• EDUCATION
  • 2021 Annual Meeting Call for Abstracts
  • Webinars
• MEETINGS & EVENTS
  • Calendar of Events
  • Webinars
  • 2021 Virtual Annual Meeting
  • 2021 Mid-Winter Meeting
  • Nuclear Medicine & Molecular Imaging Week
  • SNMMI-TS Leadership Academy
  • SNMMI Future Leaders Academy
• ADVOCACY
  • Coding & Reimbursement
  • Legislative Efforts
  • Government Relations News
  • Radiopharmaceutical Supply News
  • USP 825
  • Technologist State Issues
  • Position Statements
  • Coalition for PET Drugs
  • FDA PET Drug Manufacturing Q&A
• EVIDENCE & QUALITY
  • Clinical Guidelines and AUC
  • Quality
  • Practice Resources
  • Dose Optimization
  • About Quality & Practice
  • Dosimetry
• RESEARCH
  • Clinical Trials Network
  • Radiopharmaceutical Therapy Central
  • Preclinical Imaging
  • Nuclear Medicine Clinical Trial Group, LLC
  • Research: Learn More
• ABOUT SNMMI
  • Strategic Plan
  • Bylaws & Procedures
  • Governance - SNMMI
  • Governance - SNMMI-TS
  • History
  • Grants, Awards, and Scholarships
  • Career Center
  • About Nuclear Medicine & Molecular Imaging
  • International Collaboration
  • Outreach
  • Support SNMMI
  • Contact Us

Press Release

• New Treatment Proves More Effective and Less Toxic for Neuroendocrine Tumor Patients

  Mar 19, 2021 — A new treatment for late-stage neuroendocrine tumors has been found to be more effective and have fewer side effects than the current standard of care, according to research published in JNM.

• Immuno-PET Can Give Physicians Early Insight into Tumor Response to Targeted Therapy

  Mar 12, 2021 — Immuno-PET imaging can provide early insight into a tumor’s response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer.

• Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment

  Feb 16, 2021 — Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy, according to research published in the February issue of JNM.

• Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model

  Feb 6, 2021 — A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of JNM.

• Expanded PET Imaging Time Window Adds Convenience and Flexibility for Neuroendocrine Tumor Patients

  Jan 20, 2021 — The imaging time window of 64Cu-DOTATATE positron emission tomography/computed tomography (PET/CT) for patients with neuroendocrine neoplasms can be expanded from 1 hour to 3 hours post-injection, according to new research published in JNM.

• Potential Jurors Favor Use of Artificial Intelligence in Precision Medicine

  Jan 11, 2021 — Physicians who follow artificial intelligence advice may be considered less liable for medical malpractice than is commonly thought, according to a new study published in JNM.

• New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study

  Dec 15, 2020 — A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival, according to new research published in JNM.

• PET Imaging Tracer Proves Effective for Diagnosing and Managing Rare CNS B-Cell Lymphoma

  Dec 9, 2020 — PET imaging with Ga-68-pentixafor is an effective diagnostic tool for central nervous system B-cell lymphoma, according to a proof-of-concept study published in the December issue of JNM.

• The Journal of Nuclear Medicine Celebrates 60 Years of Research

  Dec 9, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of leadership in the field of nuclear medicine, molecular imaging and therapy.

• FDA Announces First-Ever Approval of PSMA PET for Prostate Cancer Imaging

  Dec 2, 2020 — The FDA has approved ga-68 PSMA-11 for PET imaging of PSMA–positive lesions in men with prostate cancer. It is the first approval for a PSMA PET drug in the United States.

• Multi-Center, Multi-Tracer PET Studies Harmonized to Detect Neuroinflammation in ALS

  Dec 1, 2020 — A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease.

• Novel Therapy Approach for Hyperinsulinemic Hypoglycemia

  Nov 6, 2020 — A new method to treat hyperinsulinemic hypoglycemia has proved highly selective in targeting lesions and effective in slowing tumor growth, according to research published in the November issue of JNM.

• Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug

  Oct 7, 2020 — A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research featured in the October issue of JNM.

• Cerenkov Luminescence Imaging Accurately Identifies Surgical Margin Status During Radical Prostatectomy

  Oct 6, 2020 — A new intraoperative imaging technique, Cerenkov luminescence imaging, can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research published in the October issue of JNM.

• PET/MRI Improves Lesion Detection, Reduces Radiation Exposure

  Sep 17, 2020 — A study of more than 1,000 oncological examinations has demonstrated that PET/MRI facilitates cancer staging as well as PET/CT and improves lesion detectability in select cancers, potentially helping to promote fast, efficient local and whole-body staging in one step.

• SNMMI 2020-2022 Wagner-Torizuka Fellowship Recipients Announced

  Sep 8, 2020 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2020-2022 SNMMI Wagner-Torizuka Fellowship.

• Updated Statement: COVID-19 and Ventilation/Perfusion (V/Q) Lung Studies

  Sep 3, 2020 — SNMMI has released an updated statement on COVID-19 and ventilation/perfusion (V/Q) lung studies.

• Virtual Patient Education Day Event Draws 600+ Viewers

  Aug 28, 2020 — SNMMI and its Patient Advocacy Advisory Board (PAAB) held the Society’s annual Patient Education Day this year as a series of three virtual sessions, reaching the highest number of patients in the event’s nine-year history.

• New Approach for Calculating Radiation Dosimetry Allows for Individualized Therapy

  Aug 10, 2020 — Researchers from Peter MacCallum Cancer Centre have developed a simplified dosimetry method that could enhance personalization of cancer therapy based on a single posttreatment scan.

• A Virtual Celebration of Life for Sam Gambhir, MD, PhD to take place on Friday, August 14, 2020

  Aug 8, 2020 — A Virtual Celebration of Life will take place on Friday, August 14, 2020 to honor molecular imaging pioneer Sanjiv “Sam” Gambhir, MD, PhD, who passed away on Saturday, July 18, from cancer.

• New Multiple Myeloma Therapy Shows Promise in Preclinical Study

  Aug 6, 2020 — A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to research published in JNM.

• Patient, Healthcare Provider Groups Join Together to Promote a #ReturnToCare

  Aug 4, 2020 — More than a dozen patient advocacy organizations and medical societies have formed a coalition to promote public health by encouraging patients to seek necessary screenings, vaccinations, scans, and treatments that have been put off as a result of concerns about COVID-19.

• Genomic Signature Explains FDG-Avidity of PSMA-Suppressed Prostate Tumors

  Jul 22, 2020 — Scientists from the University of Windsor have investigated why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the prostate-specific membrane antigen (PSMA).

• Molecular Imaging Pioneer Sam Gambhir Passes Away

  Jul 19, 2020 — Molecular imaging pioneer Sanjiv “Sam” Gambhir, MD, PhD, passed away on Saturday, July 18, from cancer.

• SNMMI Announces Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT) as President-Elect of the Technologist Section During 2020 Annual Meeting

  Jul 14, 2020 — Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT), has been elected as the 2020-21 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section.

• SNMMI Announces Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, as President of Technologist Section during 2020 Annual Meeting

  Jul 14, 2020 — Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, has been named 2020-21 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section.

• SNMMI Image of the Year: Super-Agers Show Resistance to Tau and Amyloid Accumulation, Maintain High Cognitive Function

  Jul 14, 2020 — Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have been found to have increased resistance to tau and amyloid proteins, according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting.

• SNMMI Elects Richard L. Wahl, MD, as President-Elect During 2020 Annual Meeting

  Jul 13, 2020 — Richard L. Wahl, MD, has been elected 2020-21 president-elect of the Society of Nuclear Medicine and Molecular Imaging.

• SNMMI Elects Alan B. Packard, PhD, as President During 2020 Annual Meeting

  Jul 13, 2020 — Alan Packard, PhD, has been elected 2020-21 president of the Society of Nuclear Medicine and Molecular Imaging.

• Society of Nuclear Medicine and Molecular Imaging Announces 2020 Fellows

  Jul 13, 2020 — The Society of Nuclear Medicine and Molecular Imaging recognized 10 new SNMMI Fellows on Monday, July 13, during a plenary session at the society’s 2020 Annual Meeting.

• SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as Vice President-Elect During 2020 Annual Meeting

  Jul 13, 2020 — Munir Ghesani, MD, FACNM, FACR, has been named as vice president-elect for the Society of Nuclear Medicine and Molecular Imaging.

• Novel Bone Imaging Approach Provides Insights into the Progression of Knee Osteoarthritis

  Jul 12, 2020 — A new approach to functional bone imaging has established that bone metabolism is abnormally elevated in patients with knee osteoarthritis.

• Total-Body Dynamic PET Successfully Detects Metastatic Cancer; First Patient Results Reported

  Jul 12, 2020 — Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.

• In Recurrent Prostate Cancer, PSMA PET/CT Changes Management in Two-Thirds of Cases

  Jul 12, 2020 — New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent disease in prostate cancer patients.

• Molecular Imaging Identifies Link between Heart and Kidney Inflammation after Heart Attack

  Jul 12, 2020 — Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction, or heart attack.

• Carolyn J. Anderson, PhD, Receives SNMMI 2020 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jul 12, 2020 — Carolyn J. Anderson, PhD, has been named the 2020 recipient of the prestigious Paul C. Aebersold Award. Anderson is a professor in the departments of medicine, radiology, bioengineering, chemistry, and pharmacology and chemical biology at the University of Pittsburgh in Pennsylvania.

• Stephen L. Bacharach, PhD, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

  Jul 12, 2020 — Stephen L. Bacharach, PhD, a physicist known for his research in cardiac and PET oncology imaging, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• New PET Radiotracer Proven Safe and Effective in Imaging Malignant Brain Tumors

  Jul 12, 2020 — A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas.

• New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management

  Jul 11, 2020 — A new molecular imaging approach utilizing 18F-FDG positron emission tomography (PET) and magnetic resonance imaging can precisely identify the location of pain generators in chronic pain sufferers, often precipitating a new management plan for patients.

• Total-Body PET/CT Captures Full Picture of Systemic Inflammatory Arthritis

  Jul 11, 2020 — For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneously across all joints and organ systems, using the high-sensitivity, high-resolution uEXPLORER total-body positron emission tomography/computed tomography scanner

• Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

  Jul 11, 2020 — Targeted radionuclide therapy has been found to create a favorable tumor microenvironment in prostate cancer that improves the effectiveness of immunotherapies.

• Novel Radiotracer Measures Synaptic Activity After Stroke

  Jul 11, 2020 — A new radiotracer, 18F-SynVesT-2, can directly assess synaptic density changes in the brain, providing an objective and quantitative measure of disease progression after stroke.

• New Theranostic Agents Demonstrate Efficacy in Treatment of Prostate Cancer in Preclinical Studies

  Jul 11, 2020 — Researchers have developed a new pair of agents that show exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies.

• Journal of Nuclear Medicine Impact Factor Jumps More than Seven Percent

  Jun 29, 2020 — The Journal of Nuclear Medicine has achieved the highest impact factor ever in its 6o-year history, ranking fourth among all medical journals worldwide, according to new data just released in the 2019 Journal Citation Reports published by Clarivate Analytics.

• Novel Radiotracer Proves Advantageous for Imaging Neuroendocrine Tumor Patients with Liver-Dominant Disease

  Jun 24, 2020 — For neuroendocrine cancer patients with liver metastases, a new radiopharmaceutical has shown excellent imaging performance in tumor detection, staging and restaging, providing important information to guide treatment.

• Nuclear Medicine and COVID-19: New Content from The Journal of Nuclear Medicine

  Jun 9, 2020 — Five new COVID-related articles and commentaries are published in the June issue of The Journal of Nuclear Medicine (JNM).

• New Research Reveals Potentially Treatable Genetic Mutations in Patients Resistant to PSMA-Targeting Therapy

  May 20, 2020 — Prostate cancer patients who do not respond well to PSMA-targeted therapy often have potentially treatable mutations in their DNA damage-repair genes, according to research published in the May issue of The Journal of Nuclear Medicine.

• Molecular Imaging Provides Insight into Therapeutic Outcomes for Neuroendocrine Tumor Patients Days after Treatment

  May 13, 2020 — Nuclear medicine can identify early response to Lu-177 DOTATATE treatment in neuroendocrine tumor patients, according to a new study in the May issue of The Journal of Nuclear Medicine.

• Novel Radiotracer Meets Gold Standard for Imaging Prostate Cancer, Offers Benefits over Established Imaging Agent

  May 8, 2020 — The novel radiopharmaceutical F-18-PSMA-1007 is effective for detecting malignant prostate cancer lesions and readily available, according to research published in the April issue of The Journal of Nuclear Medicine.

• Technologists Answer Questions about COVID-19

  May 5, 2020 — The COVID-19 crisis has forced nuclear medicine departments to cancel appointments, change procedures and protocols and adapt rapidly to significant changes. To provide guidance to the community, SNMMI-TS interviewed eight nuclear medicine technologists from around the country.

• Announcement: SNMMI Annual Meeting

  Apr 30, 2020 — SNMMI President Vasken Dilsizian, MD, shares an important message unveiling the re-imagined SNMMI 2020 Annual Meeting—Virtual Edition.

• Travel Considerations Specified for Lu-177-DOTATATE Radiation Therapy Patients

  Apr 24, 2020 — A team of researchers and patient advocates has addressed the challenges related to traveling after receiving Lu-177-DOTATATE radiation therapy in a study published in The Journal of Nuclear Medicine.

• New Therapy Option Identified for Early-Stage Breast Cancer

  Jan 29, 2020 — Radionuclide therapy has been successful in delaying the growth of disseminated tumor cells in early-stage breast cancer. Radium-233 dichloride not only impacts cells directly hit by radiation but also has significant effects on cells outside of the radiation field, according to research published in The Journal of Nuclear Medicine.

• Marta Cremonesi, PhD, Selected as the 2020 Loevinger-Berman Award Recipient

  Jan 8, 2020 — The SNMMI Medical Internal Radiation Dose (MIRD) Committee has selected Marta Cremonesi, PhD, as the 2020 Loevinger-Berman Awardee, recognizing a lifetime of achievements and contributions to medical internal dosimetry.

• New Radiotracer Offers Opportunities for Earlier Intervention after Heart Attack

  Dec 18, 2019 — A new radiotracer can effectively image fibroblast activation after a heart attack, identifying a window of time during which cardiac fibrosis can be prevented and the disease course altered. The study is featured in The Journal of Nuclear Medicine.

• Finding a Non-invasive Way to Predict Effectiveness of Cancer Therapy

  Dec 12, 2019 — Researchers have taken a critical step toward developing a non-invasive nuclear medicine technique that can predict the effectiveness of therapy for cancerous tumors, allowing for personalized, precision treatment. The study is featured in the December issue of The Journal of Nuclear Medicine.

• Novel Theranostic Reagent Could Enhance Detection and Therapy of Prostate Cancer

  Nov 26, 2019 — A novel nuclear medicine radiotracer could help identify the extent of metastatic prostate cancer and select patients for therapy. The study is featured in The Journal of Nuclear Medicine.

• New Technique Could Optimize PSMA-Targeted Prostate Cancer Therapy

  Nov 13, 2019 — Researchers have discovered a new way to optimize results in treating patients with prostate cancer tumors while minimizing negative side effects. The study is featured in the November issue of The Journal of Nuclear Medicine.

• Therapy for Neuroendocrine Tumors May Be Improved by Patient-Specific Dosimetry

  Oct 28, 2019 — In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment, according to new research published in The Journal of Nuclear Medicine.

• Optoacoustic Imaging Shows Potential for Noninvasive Diagnostics for Thyroid Disorders

  Oct 22, 2019 — A new noninvasive imaging technique can provide novel biomarker information for initial evaluation and differential diagnosis of thyroid disorders.

• PET Offers More Precise Screening Method to Select Candidates for Radionuclide Therapy

  Sep 24, 2019 — PET scanning can offer more precise selection of patients for neuroendocrine tumor therapy, allowing some patients to qualify who would otherwise have been ineligible, according to an article featured in The Journal of Nuclear Medicine.

• Bipartisan Group Moves to Expand Access to Diagnostic Radiopharmaceuticals

  Jul 17, 2019 — On July 16, a bipartisan group introduced the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (HR 3772). The bill would expand patient access to highly targeted, precision diagnostic radiopharmaceuticals that evaluate conditions such as Alzheimer’s disease, Parkinson’s disease, and some cancers—allowing patients to get the right treatment faster and saving taxpayers money.

• Influence of The Journal of Nuclear Medicine Jumps 25 Percent

  Jun 27, 2019 — The Journal of Nuclear Medicine again ranks among the top five medical imaging journals in the world. JNM continues to lead among nuclear medicine journals, with the highest impact factor (7.354), the highest immediacy index, the highest number of citations, the highest 5-year impact factor, the highest number of citable articles, and the highest influence score.

• Molecular Imaging Suggests Smokers May Have Impaired Neuroimmune Function

  Jun 25, 2019 — Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNM MI) shows preliminary evidence that tobacco smokers may have reduced neuroimmune function compared with nonsmokers.

• Ultrasmall Nanoclusters and Carbon Quantum Dots Show Promise for Treating Acute Kidney Injury

  Jun 25, 2019 — Two research studies offer hope for effective treatment and prevention on acute kidney injury.

• New Combination Therapy Established as Safe and Effective for Prostate Cancer

  Jun 25, 2019 — A novel therapy using two targeted treatments for prostate cancer has been shown to maximize efficacy while reducing side effects.

• SNMMI Image of the Year: Novel Radiotracer Detects 28 Cancer Types, Paving the Way for Development of New Therapies

  Jun 25, 2019 — Each year, the SNMMI chooses an image that best exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. This year the honor goes to a team of researchers at University Hospital Heidelberg, Germany. Showcasing the efficacy of the FAPI radiotracer, the image demonstrates the uptake of the FAPI in 12 epidemiological tumor entities, including high uptake values in lung, breast, prostate, esophageal and pancreatic cancer.

• Society of Nuclear Medicine and Molecular Imaging Announces 2019 Fellows

  Jun 25, 2019 — The Society of Nuclear Medicine and Molecular Imaging recognized 13 new SNMMI Fellows on Monday, June 24, during the Monday plenary session at the society’s 2019 Annual Meeting, held June 22-25 in Anaheim, California.

• Radionuclide Therapy Effective in High-Grade Neuroendocrine Neoplasms

  Jun 25, 2019 — Peptide receptor radionuclide therapy (PRRT) has been shown to be safe and effective for patients with grade 3 (G3) neuroendocrine neoplasms (NENs), according to research presented at SNMMI's 2019 Annual Meeting.

• Wearable Technology to Personalize Lu-177-DOTATATE Therapy for NETs

  Jun 24, 2019 — Researchers at the University of Washington in Seattle, Washington, are developing a user-friendly (worn at home) vest with technology that collects data to tailor personalized therapy for patients with metastatic, somatostatin-receptor-2 positive neuroendocrine tumors (NETs).

• Nuclear Medicine PSMA-Targeted Study Offers New Options for Cancer Theranostics Worldwide

  Jun 24, 2019 — Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) describes a new class of radiopharmaceuticals—radiohybrids—that offer a fresh perspective on cancer imaging and radioligand therapy (theranostics). In addition, the technology encompasses a highly innovative and efficient isotopic labeling method to facilitate broad application.

• SNMMI Elects Richard L. Wahl, MD, as Vice President-Elect During 2019 Annual Meeting

  Jun 24, 2019 — Richard L. Wahl, MD, has been elected as 2019-20 vice president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Wahl is the Elizabeth E. Mallinckrodt Professor and head of radiology at Washington University School of Medicine in St. Louis, director of the university’s Mallinckrodt Institute of Radiology and a professor of radiation oncology.

• SNMMI Elects Alan B. Packard, PhD, as President-Elect During 2019 Annual Meeting

  Jun 24, 2019 — Alan Packard, PhD, has been elected as 2019-20 president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Packard is associate professor of radiology at Harvard Medical School, director of radiopharmaceutical research and a senior research associate in nuclear medicine at Boston Children's Hospital, and research associate in nuclear medicine at Brigham and Women’s Hospital in Boston, Massachusetts.

• SNMMI Elects Vasken Dilsizian, MD, as President During 2019 Annual Meeting

  Jun 24, 2019 — Vasken Dilsizian, MD, professor of radiology and medicine at the University of Maryland School of Medicine and chief of the Division of Nuclear Medicine at the University of Maryland Medical Center in Baltimore, Maryland, has assumed office as 2019-20 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

• Earlier Diagnosis and Treatment Assessment of Tuberculosis Achieved with PET/CT

  Jun 24, 2019 — Research presented at SNMMI's 2019 Annual Meeting shows that molecular imaging with 18F-FDG PET/CT can evaluate tuberculosis at the molecular level, effectively identifying diseased areas and guiding treatment for patients.

• SNMMI Announces Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, as President-Elect of Technologist Section During 2019 Annual Meeting

  Jun 24, 2019 — Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, has been named 2019-2020 president-elect of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). Buehner is a health physicist specialist at Rush University Medical Center in Chicago, Illinois.

• SNMMI Announces Mark H. Crosthwaite, MEd, CNMT, PET, NMTCB(S), FSNMMI-TS, as President of Technologist Section During 2019 Annual Meeting

  Jun 24, 2019 — Mark H. Crosthwaite, MEd, CNMT, PET, NMTCB(S), FSNMMI-TS, associate professor and program director of the baccalaureate nuclear medicine technology program, Department of Radiation Sciences, at Virginia Commonwealth University, Richmond, Virginia, has been named 2019-2020 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• Marcelo F. Di Carli, MD, Receives the SNMMI 2019 Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 23, 2019 — Marcelo F. Di Carli, MD, was presented the Georg Charles de Hevesy Nuclear Pioneer Award for his contributions to nuclear medicine at the SNMMI 2019 Annual Meeting, in Anaheim, California.

• Jason S. Lewis, PhD, Receives SNMMI 2019 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 23, 2019 — Jason S. Lewis, PhD, was presented the prestigious Paul C. Aebersold Award during the SNMMI 2019 Annual Meeting, June 22-25 in Anaheim, California.

• Interim Scan during Prostate Cancer Therapy Helps Guide Treatment

  Jun 23, 2019 — New prostate cancer research shows that adding an interim scan during therapy can help guide a patient’s treatment. The research was presented at the SNMMI 2019 Annual Meeting.

• PET/CT Detects Cardiovascular Disease Risk Factors in Obstructive Sleep Apnea Patients

  Jun 23, 2019 — Research presented at SNMMI’s 2019 Annual Meeting draws a strong link between severe obstructive sleep apnea and impaired coronary flow reserve, which is an early sign of the heart disease atherosclerosis.

• Novel Noninvasive Molecular Imaging for Monitoring Rheumatoid Arthritis

  Jun 23, 2019 — A first-in-human Phase 1/Phase II study demonstrates that intravenous administration of the radiopharmaceutical imaging agent technetium-99m (99mTc) tilmanocept promises to be a safe, well-tolerated, noninvasive means of monitoring rheumatoid arthritis disease activity. The study was presented at the SNMMI 2019 Annual Meeting.

• Early Biomarker Found for Degenerative Neurologic Disease

  Jun 22, 2019 — Researchers have discovered a novel radioligand that can effectively differentiate progressive supranuclear palsy from similar brain disorders, allowing for earlier and more reliable diagnosis of the disease.

• Immuno-PET Precisely Diagnoses IBD Inflammation without Invasive Procedures

  Jun 17, 2019 — Inflammation in inflammatory bowel disease can be quickly and precisely diagnosed using a new type of nuclear medicine scan. In addition, immuno-PET has high potential for theranostic diagnosis and precision treatment of IBD and other inflammatory diseases. The research is featured in the June issue of The Journal of Nuclear Medicine.

• New Radiotracer Can Identify Nearly 30 Types of Cancer

  Jun 7, 2019 — A novel class of radiopharmaceuticals has proven effective in non-invasively identifying nearly 30 types of malignant tumors. Using 68Ga-FAPI PET/CT, researchers were able to image the tumors with very high uptake and image contrast, paving the way for new applications in tumor characterization, staging and therapy. The research is featured in the June issue of The Journal of Nuclear Medicine.

• Coronary Artery Disease Diagnosis Improved by Deep Learning Analysis of SPECT MPI

  May 27, 2019 — A multicenter international study has demonstrated that diagnosis of obstructive coronary artery disease can be improved through deep learning analysis of SPECT myocardial perfusion imaging. The research is featured in the May issue of The Journal of Nuclear Medicine.

• Nuclear Medicine Therapy Shows Long-Term Effectiveness for Malignant Neuroendocrine Tumors

  Apr 26, 2019 — A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life. The study is featured in the April issue of The Journal of Nuclear Medicine.

• SNMMI and ACR Collaborate on Clinical Data Registry for Nuclear Medicine

  Apr 8, 2019 — SNMMI and the American College of Radiology announce a new collaborative clinical data registry to support high-quality practice and patient care. The registry will allow collection and analysis of data on nuclear medicine procedures, supporting continuous improvement of patient care.

• New PET Imaging Biomarker Could Better Predict Progression of Alzheimer’s Disease

  Apr 4, 2019 — Researchers have discovered a way to better predict progression of Alzheimer’s disease. A study utilizing positron emission tomography to image microglial activation levels showed that these levels could predict current and future cognitive performance better than beta-amyloid levels. The research is published in the April issue of The Journal of Nuclear Medicine.

• First Total-Body PET/CT Studies Show Potential for Better, Faster, Lower-Dose Images

  Mar 29, 2019 — The first human case studies from the first total-body PET/CT scanner show enhanced image quality, reduced scan time, a longer time window to perform the scan, reduced dose and total-body dynamic imaging, among other benefits and possibilities. The research is published in the March issue of The Journal of Nuclear Medicine.

• New Tracers Improve Diagnosis of Cancer and May Be Useful for Treatment

  Mar 11, 2019 — Researchers have identified two new nuclear medicine tracers that make it easier to diagnose and potentially treat multiple types of cancer, providing high-quality images with less patient preparation and shorter acquisition times.

• Nuclear Medicine Imaging Monitors Effectiveness of Therapy for Melanoma Patients

  Mar 5, 2019 — Nuclear medicine imaging with PET/CT can monitor the effectiveness of immunotherapy treatment for metastatic melanoma and predict outcome. In this way, a patient’s therapy can be more effectively tailored to his or her personal response.

• Novel PET/CT Imaging Agent Shows Promise for Safe and Effective Diagnosis of Acute Venous Thromboembolism

  Feb 15, 2019 — Researchers report that a new nuclear medicine tracer may allow better diagnosis of acute venous thromboembolism (VTE). Acute VTE is a disease that includes deep-vein thrombosis and its complication, pulmonary embolism, which can be fatal. The research is featured in the February issue of The Journal of Nuclear Medicine.

• PET Imaging Agent May Allow Early Measurement of Efficacy of Breast Cancer Therapy

  Feb 11, 2019 — Physicians may soon have a new way to measure the efficacy of hormone therapy for breast cancer patients, according to research published in the February issue of The Journal of Nuclear Medicine.

• Combined SPECT and Cardiac MR Imaging Can Help Guide Ventricular Tachycardia Ablation

  Jan 30, 2019 — Adding functional imaging to structural imaging of patients with ventricular tachycardia (VT) has the potential to improve current VT ablation strategies, according to new research published in the January 2019 issue of The Journal of Nuclear Medicine.

• New PET Probe Could Improve Detection of Primary and Metastatic Melanoma

  Jan 16, 2019 — A new nuclear medicine method for detecting malignant melanoma, one of the most aggressive skin cancers, has been successfully tested for the first time in humans and could improve detection of both primary and metastatic melanoma. The research is featured in the January 2019 issue of The Journal of Nuclear Medicine.

• Whole Body PET/MRI Provides One-Stop-Shop for Staging of High-Risk Prostate Cancer Patients

  Dec 11, 2018 — New research shows that molecular imaging—specifically, PSMA PET/MR—performs as well as currently used tools and provides additional information on tumor location that could help guide treatment for prostate cancer patients.

• New PET Tracer Identified for Imaging Tau in Alzheimer’s Disease Patients

  Dec 5, 2018 — Researchers have identified a promising second-generation positron emission tomography (PET) tracer for imaging and measuring tau pathology, contributing to understanding of Alzheimer’s and related dementias.

• SNMMI Welcomes Cardinal Health to Value Initiative Leadership

  Nov 12, 2018 — SNMMI is pleased to announce that Cardinal Health has joined the SNMMI’s Value Initiative Industry Alliance.

• Prostate Cancer Radiotherapy More Precisely Targeted with Nuclear Medicine Imaging

  Nov 8, 2018 — A nuclear medicine imaging procedure can pinpoint prostate cancer with superior accuracy, allowing more precisely targeted treatment, according to new research featured in the November 2018 issue of The Journal of Nuclear Medicine.

• Novel Tracer Developed for Precision Targeting of Non-Small Cell Lung Cancer

  Nov 5, 2018 — New research shows PET imaging with the 18F-FAC radiotracer can be used as a non-invasive substitute for liver biopsies. The study is featured in the October issue of The Journal of Nuclear Medicine.

• SNMMI Expresses Support of H.R. 6948: The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018

  Oct 4, 2018 — The Society of Nuclear Medicine and Molecular Imaging commend Congressmen George Holding (NC-2) and Seth Moulton (MA-6) for introducing H.R. 6948.

• New Study Evaluates Efficacy of PET Imaging to Manage Chronic Liver Diseases

  Oct 4, 2018 — New research shows PET imaging with the 18F-FAC radiotracer can be used as a non-invasive substitute for liver biopsies. The study is featured in the October issue of The Journal of Nuclear Medicine.

• New Nuclear Medicine Tracer Will Help Study the Aging Brain

  Oct 3, 2018 — A new PET imaging radiotracer could help researchers understand neurodegenerative disease and the aging brain.

• SNMMI 2018-2020 Wagner-Torizuka Fellowship Recipients Announced

  Sep 20, 2018 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2018-2020 SNMMI Wagner-Torizuka Fellowship.

• Researchers Identify Pitfall in Popular Prostate Cancer PET Imaging Method

  Sep 7, 2018 — Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has become a popular method for determining the stage of a patient’s prostate cancer. However, researchers have identified a major pitfall in this imaging technique and are cautioning medical professionals to be aware of the potential for misdiagnosis.

• New Nuclear Medicine Imaging Method Shows Strong Potential for Cancer Imaging

  Sep 5, 2018 — A new nuclear medicine imaging method could help diagnose widespread tumors, such as breast, colon, pancreas, lung and head and neck cancer better than current methods, with less inconvenience to patients and with equal or improved accuracy.

• SNMMI Honors Outstanding Contributors at 2018 Annual Meeting

  Aug 13, 2018 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization, recognized contributions to the field of nuclear medicine and molecular imaging during its 2018 Annual Meeting in Philadelphia. Several awards ceremonies were held to recognize the valuable role SNMMI members play in advancing the diagnosis and treatment of heart disease, cancer and neurological conditions.

• PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients

  Aug 6, 2018 — In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the metastases. However, little is known about ER expression across metastases throughout the body and surrounding normal tissue. Using a PET tracer, researchers in the Netherlands have been able to identify differences in ER expression, which could help guide treatment for metastatic breast cancer patients. The study is featured in The Journal of Nuclear Medicine’s August issue.

• Novel PET Imaging Method Could Track and Guide Therapy for Type 1 Diabetes

  Aug 2, 2018 — Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The new PET imaging method could measure beta-cell mass, which would greatly enhance the ability to monitor and guide diabetes therapies. This study is reported in the featured article of the month in The Journal of Nuclear Medicine’s August issue.

• SNMMI Technologist Section Announces 2018 Award Winners

  Jul 30, 2018 — SNMMI’s Technologist Section (SNMMI-TS) recognized contributions to and work in the field of nuclear medicine and molecular imaging during the SNMMI 2018 Annual Meeting in Philadelphia. Several awards ceremonies were held to recognize the valuable role that SNMMI-TS members play in advancing the discipline of nuclear medicine technology.

• The Journal of Nuclear Medicine Impact Factor Increases by 12 Percent

  Jul 18, 2018 — The Journal of Nuclear Medicine (JNM)—SNMMI's flagship publication—has again been ranked among the top medical imaging journals worldwide, according to new data released in the 2017 Journal Citation Reports© published by Clarivate Analytics. JNM’s impact factor went up from 6.646 (2016) to 7.439 (2017).

• Novel PET Imaging Method More Fully Evaluates Extent of Rheumatoid Arthritis Inflammation

  Jul 9, 2018 — A new PET imaging method more fully evaluates the extent of rheumatoid arthritis by targeting translocator protein (TSPO) expression in the synovium (joint lining tissue). The study is featured in the July issue of The Journal of Nuclear Medicine.

• Novel Pretargeted Radionuclide Therapy for HER2-Expressing Cancers Shows Promise

  Jul 2, 2018 — In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves survival. The study is reported in The Journal of Nuclear Medicine’s July featured article of the month.

• SNMMI 65th Annual Meeting Sets the Stage for a Revolution in Precision Medicine

  Jun 28, 2018 — More than 5,000 physicians, technologists, scientists and exhibitors gathered for the Society of Nuclear Medicine and Molecular Imaging’s 65th Annual Meeting, held June 23-26 in Philadelphia. With nuclear medicine playing a growing role in providing precision medicine, theranostics (combining diagnostic imaging and targeted radionuclide therapy) were an important focus throughout the meeting.

• Fluciclovine PET/CT Locates Recurrent Prostate Cancer and Advises Management

  Jun 26, 2018 — The addition of fluorine-18-fluciclovine PET/CT to the diagnostic work-up of patients with biochemical recurrence of prostate cancer locates previously undetected lesions and changes treatment management for the majority of patients, according to a clinical trial report presented at the SNMMI 2018 Annual Meeting.

• SNMMI Announces Mark H. Crosthwaite, MEd, CNMT, PET, NMTCB(S), FSNMMI-TS, as President-Elect of Technologist Section during 2018 Annual Meeting

  Jun 26, 2018 — Mark H. Crosthwaite, MEd, CNMT, PET, NMTCB(S), FSNMMI-TS, associate professor and program director of the baccalaureate nuclear medicine technology program, Department of Radiation Sciences, at Virginia Commonwealth University, Richmond, Virginia, has been named 2018-2019 president elect of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• SNMMI Announces Norman E. Bolus, MSPH, MPH, CNMT, FSNMMI-TS, as President of Technologist Section During 2018 Annual Meeting

  Jun 26, 2018 — Norman E. Bolus, MSPH, MPH, CNMT, FSNMMI-TS, has been elected as the 2018-2019 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). The new slate of officers was introduced during the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2018 Annual Meeting, June 23–26 in Philadelphia, Pennsylvania.

• Society of Nuclear Medicine and Molecular Imaging Announces 2018 Fellows

  Jun 26, 2018 — The Society of Nuclear Medicine and Molecular Imaging recognized 14 new SNMMI Fellows on June 25 during a Special Plenary Session at the society’s 2018 Annual Meeting, held June 23-26 in Philadelphia.

• SNMMI Image of the Year: PSMA PET Imaging of Theranostic for Advanced Prostate Cancer

  Jun 26, 2018 — In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting PSMA with the radionuclide lutetium-177. At the SNMMI 2018 Annual Meeting, researchers reported on a phase II prospective trial. Using gallium-68-PSMA11 PET imaging, men who had exhausted conventional therapies were screened. Those with high PSMA-expression proceeded to 177Lu-PSMA617 (LuPSMA) therapy and experienced high response rates, which is clearly demonstrated in the PSMA PET imaging figure selected as the 2018 SNMMI Image of the Year.

• Early Treatment of Advanced Prostate Cancer with PSMA-Targeted Radioligand Therapy Prolongs Life

  Jun 26, 2018 — Research presented at the SNMMI 2018 Annual Meeting demonstrates for the first time the benefit of providing earlier lutetium-177 prostate-specific membrane antigen (PSMA) radioligand therapy to patients with metastatic prostate cancer. Until now, this therapy has only been used in patients with end-stage disease.

• SNMMI Elects Satoshi Minoshima, MD, PhD, as President During 2018 Annual Meeting

  Jun 25, 2018 — Satoshi Minoshima, MD, PhD, professor and chair of the Department of Radiology and Imaging Sciences at the University of Utah, Salt Lake City, Utah, has assumed office as 2018-19 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2018 Annual Meeting, June 23–26 in Philadelphia.

• SNMMI Elects Vasken Dilsizian, MD, as President-Elect During 2018 Annual Meeting

  Jun 25, 2018 — Vasken Dilsizian, MD, professor of radiology and medicine at the University of Maryland School of Medicine and chief of the Division of Nuclear Medicine at the University of Maryland Medical Center in Baltimore, Maryland, has assumed office as 2018-19 president-elect of SNMMI.

• New Theranostic Strategy Developed for Precise Tumor Diagnosis and Therapy

  Jun 25, 2018 — A novel, intelligent theranostic agent for precise tumor diagnosis and therapy has been developed that remains as small molecules while circulating in the bloodstream, can then self-assemble into larger nanostructures in the tumor, and be activated by the tumor microenvironment for therapy guided by photoacoustic imaging. The research was presented at the SNMMI 2018 Annual Meeting.

• Sanjiv Sam Gambhir, MD, PhD, Receives 2018 Benedict Cassen Prize for Research in Molecular Imaging

  Jun 25, 2018 — Sanjiv Sam Gambhir, MD, PhD, known for his pioneering work in multimodality molecular imaging, was awarded the Benedict Cassen Prize during the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Philadelphia, Pa. This honor is awarded every two years by the Education and Research Foundation for Nuclear Medicine and Molecular Imaging in recognition of outstanding achievement and work leading to a major advance in nuclear medicine science.

• SNMMI Elects Alan B. Packard, PhD, as Vice President-Elect at 2018 Annual Meeting

  Jun 25, 2018 — Alan Packard, PhD, has been elected as 2018-19 vice president-elect of SNMMI. He is associate professor of radiology at Harvard Medical School, director of radiopharmaceutical research and a senior research associate in nuclear medicine at Boston Children's Hospital, and a research associate in nuclear medicine at Brigham and Women’s Hospital in Boston, Massachusetts.

• Richard L. Wahl, MD, Receives SNMMI 2018 Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 24, 2018 — Richard L. Wahl, MD, FACNM, FACR, has been named this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award for his contributions to nuclear medicine. Wahl is the Elizabeth E. Mallinckrodt Professor and head of radiology at Washington University School of Medicine in St. Louis, director of the university’s Mallinckrodt Institute of Radiology and a professor of radiation oncology. He was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2018 Annual Meeting, June 23-26 in Philadelphia.

• Simon Cherry, PhD, Receives SNMMI 2018 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 24, 2018 — Simon R. Cherry, PhD, Distinguished Professor at the University of California, Davis, has been named the 2018 recipient of the prestigious Paul C. Aebersold Award. Cherry was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its Annual Meeting, June 23-26 in Philadelphia, PA.

• New Nuclear Medicine Technique Could Help Tackle Brain Disease

  Jun 24, 2018 — A new molecular imaging method can monitor the success of gene therapy in all areas of the brain, potentially allowing physicians to more effectively tackle brain conditions such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosis. The research was presented today at the SNMMI 2018 Annual Meeting, June 23-26 in Philadelphia.

• Novel Nuclear Medicine Approach Shows Promise for Treating Wide Array of Cancerous Tumors

  Jun 24, 2018 — A novel nuclear medicine approach is showing great promise for precision treatment of solid tumors in many types of cancer—including lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma and sarcoma in children. The research was presented today at the SNMMI 2018 Annual Meeting, June 23-26 in Philadelphia.

• Novel Nuclear Medicine Probe Will Help Assess New Drugs for Neurodegenerative Diseases

  Jun 24, 2018 — New nuclear medicine tracers could help medical researchers find a cure for Alzheimer’s and other neurodegenerative diseases. The research was presented today at the SNMMI 2018 Annual Meeting, June 23-26 in Philadelphia.

• Combining Targeted Radionuclide Therapy and Immunotherapy Could Improve Melanoma Survival

  Jun 24, 2018 — Research presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows that combining targeted radionuclide therapy with immunotherapy could improve the survival of patients with metastatic melanoma.

• Novel Long-Lasting Radionuclide Therapy for Advanced Neuroendocrine Tumors Proves Effective

  Jun 24, 2018 — A first-in-human study presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates the benefits and safety of a new, long-lasting type of radionuclide therapy for patients with advanced, metastatic neuroendocrine tumors (NETs).

• Novel PET Tracer Successfully Images Cardiovascular Infections

  Jun 23, 2018 — A novel positron emission tomography (PET) tracer has been developed that can accurately image cardiovascular infections, which are extremely dangerous and have a high fatality rate. The research was presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

• Improved PSMA-Targeting Agent More Effective for Prostate Cancer Diagnosis and Therapy in Mice

  Jun 23, 2018 — Research presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates a potentially more effective method of imaging and treating prostate cancer that modifies a prostate-specific membrane antigen (PSMA)-targeted radioligand by adding an albumin-binding Evans blue (an azo dye) derivative.

• WMIS, ACR and SNMMI Urge CMS to Reopen Reconsideration for NaF PET

  Jun 7, 2018 — Medicare patients with metastatic cancers may be negatively impacted by the recent decision of the Centers for Medicare & Medicaid Services (CMS) to decline to provide coverage for 18F-sodium fluoride positron emission tomography (NaF PET) imaging.

• New Nuclear Medicine Method Shows Promise for Better Detection of Neuroendocrine Tumors

  Jun 6, 2018 — Researchers have shown that a new nuclear medicine procedure could safely and more effectively detect cancerous gastrointestinal and pancreatic neuroendocrine tumors than current methods. The study is featured in the June issue of The Journal of Nuclear Medicine.

• Novel PET Imaging Noninvasively Pinpoints Colitis Inflammation Sites

  Jun 4, 2018 — A novel positron emission tomography (PET) imaging method shows promise for noninvasively pinpointing sites of inflammation in people with inflammatory bowel disease, which includes ulcerative colitis and Crohn’s disease. The University of California, Los Angeles (UCLA), study is featured in the June issue of The Journal of Nuclear Medicine.

• SNMMI 2018 Annual Meeting: Imaging the Future of Human Health

  May 31, 2018 — The SNMMI 2018 Annual Meeting will be held at the Pennsylvania Convention Center in Philadelphia, PA, June 23–26. It will bring together physicians, technologists, pharmacists and scientists from around the globe to share research, network, and collaborate on “Imaging the Future of Human Health.”

• SNMMI Collaborates with Industry to Advance the Field of Nuclear Medicine and Molecular Imaging

  May 17, 2018 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Value Initiative Industry Alliance brings members of the corporate community to the table as key players in building the future of nuclear medicine and molecular imaging and demonstrating to the medical community, regulators, patients and the public their crucial role in delivering the highest quality of care.

• PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

  May 3, 2018 — A novel PET tracer developed by Korean researchers can visualize joint inflammation and could provide early diagnosis of rheumatoid arthritis, a common autoimmune disease that causes chronic inflammation of joints and can lead to deformity and dysfunction. The study is reported in the featured basic science article in The Journal of Nuclear Medicine’s May issue.

• Novel Theranostic Approach for Treating Pancreatic Cancer Patients Shows Promise

  May 1, 2018 — German researchers have developed a novel diagnostic and therapeutic (theranostic) procedure for patients with ductal pancreatic adenocarcinoma, a deadly cancer with an extremely poor prognosis (five-year survival rate of less than 5 percent) and limited treatment options. The study is featured in the May issue of The Journal of Nuclear Medicine.